Key Highlights
● ALB closed at $101.28 on 9 October 2026, below every recent named broker target, which range from $130 to $225.
● Argus cut its target to $135 from $230 on 7 October, UBS to $150 from $175 on 5 October and Mizuho to $130 from $140 on 1 October.
● Market data shows 15 Buy, nine Hold and one Sell rating, while the second data set shows 10 Strong Buy, three Buy and nine Hold.
● At least eight of the 13 listed broker actions in the past three months lowered a target.
Albemarle Corporation (NYSE:ALB) is a constituent of the S&P 500. Its shares closed at $101.28 on Friday 9 October 2026. The two data sets disagree sharply on the average analyst target, and both sit far above the share price after a run of target cuts.
What Is the Latest Analyst Price Target?
No single consensus price target is presented here: the two data sets disagree, and both sit far above the share price after a run of target cuts.
Recent named targets on market data range from $130 to $225. Argus cut its target from $230 to $135 on 7 October 2026, UBS cut from $175 to $150 on 5 October, Mizuho cut from $140 to $130 on 1 October, and JPMorgan cut from $160 to $140 on 25 August. BMO Capital Markets reiterated a $175 target on 6 October. In August, Scotiabank cut to $190, RBC to $157 and Citigroup to $175. Because targets are being revised rapidly in a falling share price, older figures in any average may no longer be representative.
What Are Wall Street Analysts Saying?
Market data shows 25 analysts with ratings in the past 12 months: 15 Buy, 9 Hold and 1 Sell, a Moderate Buy consensus. The second data set lists 22 analysts, with 10 Strong Buy, 3 Buy and 9 Hold and no Sell, which it labels Buy.
Named rating changes include an independent ratings service upgrading the shares from Sell to Hold on 8 October, and another downgrading from Strong Buy to Hold on 20 July. Morgan Stanley holds a Reduce rating. Mizuho and JPMorgan both rate the shares Neutral, while BMO Capital Markets (Outperform), UBS (Buy) and Argus (Buy) remain positive despite lowering or holding their targets.
What Could Help the Stock Reach Higher Levels?
Analysts who remain positive generally set targets well above the $101.28 close, and even the more cautious named targets of $130 to $150 sit above it. If sentiment towards the company stabilises and brokers stop cutting estimates, the gap between the price and the targets could narrow.
What Could Prevent the Stock Reaching Higher Targets?
The pattern of revisions is the clearest risk. At least eight of the thirteen listed broker actions in the past three months lowered a target, and several cuts were large, such as Argus moving from $230 to $135. The low end of the range is as little as $83.28 on the second data set and $120 on market data, which shows broad disagreement. Morgan Stanley's Reduce rating and the single Sell rating on market data indicate that not every analyst expects a recovery.
What Should Investors Watch Next?
Meanwhile, items to watch include whether further brokers follow Argus, UBS and Mizuho in cutting targets, and whether any broker changes its rating.
Albemarle's Rapid Target Cuts Leave Any Consensus Out of Date
Albemarle closed at $101.28 on 9 October 2026, and even the more cautious named targets of $130 to $150 sit above it. Ratings are still positive in both data sets, but Morgan Stanley holds a Reduce rating, Mizuho and JPMorgan are at Neutral, and at least eight of the 13 broker actions in the past three months lowered a target, including Argus moving from $230 to $135. With the low end of the range as little as $83.28 in the second data set and $120 in market data, older figures in any average may no longer be representative.






Please wait processing your request...